CEMI
$4.85
Chembio Diagnostics
($.06)
(1.22%)
CEMI
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.24)
Revenue:  $5.27 Mil
Thursday
Nov 5
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CEMI reports earnings?
Beat
Meet
Miss

Where is CEMI's stock price going from here?
Up
Flat
Down
Stock chart of CEMI
Analysts
Summary of analysts' recommendations for CEMI
Score
Grade
Pivots
Resistance
$5.27
$5.17
$5.04

$4.94

Support
$4.81
$4.71
$4.58
Tweet
Growth
Description
CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.
Peers
Myriad GeneticsImmunomedicsQuidelCareDxMeridian BioscienceSurModics